'Audacious' CVS drops key meds from Sanofi, Novartis and more by Tracy Staton Wednesday, August 3, 2016 CVS Health raised some hackles with a 2017 formulary that barred the world’s top-selling basal insulin, blocked two cancer treatments, and excluded two pricey orphan drugs. Should drugmakers be afraid?
